

# Licensing Platform launched by USPTO –Step towards combating COVID-19 through IP

## Key Patents related to diagnosis of COVID-19

- [US7933721B2](#)
- [US7018792B2](#)
- [US7582740B2](#)
- [US10031135B2](#)
- [US10209188B2](#)

## Diagnosis Techniques

- Micro fluidics
- Biosensors
- Photo detectors
- Immunoassays
- RT-PCR
- Computer-implemented micro particle immunoassay



US President Donald J. Trump recently proclaimed that *"IP has never been more apparent than it is now, as we continue the ongoing battle against the corona virus."* Taking inspiration from this thought, USPTO launched a web-based platform that facilitates licensing of patents related to COVID-19.

What should we know about the patents available on the platform?

**Approximately 60% patents are related to diagnostics and compounds available as potential drug candidates for COVID-19.**

The platform currently hosts 180 patents that are available for licensing. Various businesses and individuals will be able to connect with patent owners to purchase the license on their patents through this platform. In other words, this platform bridges the gap between the manufacturers and innovators which will help manufacturers in bringing new products and vaccines to the market and eventually be extremely helpful in preventing, diagnosing, and treating COVID-19.

The patents available on the platform are contributed by government research organizations such as the Federal Laboratory Consortium for Technology Transfer (FLC Business), the AUTM Innovation Marketplace (AIM), universities, and a number of federal agencies, including the National Institutes of Health, the Department of Energy, the National Aeronautics and Space Administration, the Food and Drug Administration, the Centers for Disease Control and Prevention, the Department of Defense and the Department of Veterans Affairs databases.

USPTO announced that most of the patents which are available for licensing are related to COVID-19 and the platform will soon facilitate patents from a variety of other key technology areas.

Bayslope analyzed these 180 patents which are available for licensing on the web-based USPTO platform '[Patents 4 Partnership](#)'.

## Key Patents related to Biologics of COVID-19

- [US9975885B2](#)
- [US20190256579A1](#)
- [US20200061185A1](#)
- [US8802822B2](#)

## Types of Biologics

- Anti-viral Drugs
- Immunogens
- Vaccines

# Offered Technology Solutions

Chart 1 provides a glimpse of the distribution of 180 patents into relevant technology domains. While almost half of the patent set relates to biologics and diagnosis techniques available to fight against COVID-19, there is a significant pool available that covers aspects such as medical supplies, drug delivery, and use of robotics in handling the pandemic.




Chart 1

## Exemplary Technology Solutions

**Diagnosis**- 23% of the total patents are related to diagnosis also covers assets which aid in detection of hazardous biochemical and contaminants in the environment. One such exemplary patent is [US10209188B2](#) that illustrated the use of an unmanned aerial vehicle including various sensors to detect the hazardous substances in air. Such a patent can be deployed in public places and healthcare facilities to safeguard population and can reduce the overall number of cases. Controlling the spread of COVID-19 by way of developing a vaccine or drug may take months but using such technology can immediately help in reducing the disease spread.

**Biologics**- Biologics also comprises 23% of the total number of patents which are available for license. Most of the patents provided under this domain relates to broad spectrum anti-viral drugs and attenuated virus used in creation of vaccines. One of a recently published patent application ([US20200061185A1](#)) provides an immunogen against the S strain of novel corona virus. The immunogen includes a recombinant corona virus S ecto domain trimmer promoters comprising one or two proline substitutions at or near a junction between a heptad repeat 1 (HR1) and a central helix that stabilize the S ecto domain trimmer in a perfusion conformation. There are many other similar patents that may prove its mettle in combating COVID-19 if exploited commercially.

**Therapy**-This domain may sound overlapping with biologics as most of the patents captured under this category may provide treatment options against COVID-19. However, there are some advanced treatment options available under this category including use of scaffolds and nonmaterial for therapy purposes.

The remaining one third set of patents are related to medical supply, robotics and, drug delivery and patient management. Technologies covered through the patents under these categories provide novel air masks, air purifiers, air sampling devices, and outpatient ambulatory medical care.

# Top 5 Key Licensors Involved




Chart 2

Chart 2 provides the distribution of institutions and universities which owns the patents available on USPTO platform for licensing. NASA owns maximum number of patents, while it is interesting that out of 53 patents 22 are co-assigned to GM Global. Out of 35 patents offered by US Department of Health and Human Services, 16 patents are co-owned by some corporates and Universities including Creare Inc., Veritech Limited, University of Maryland and University of Minnesota.

For more details related to the technology solutions offered by companies on this platform, please contact us. We will be happy to help you in any possible way.

## Key Points

1. While most of the pharmaceutical companies are collaborating to offer the closest possible therapy options, R&D sector should leverage on key available patents to develop new and better solutions in parallel.
2. Similar contribution should be offered by government agencies of other countries, thereby contributing their bit towards the fight against this global crisis.
3. Cross-selling can be another option to come up with feasible medical solution in lesser time.

## Contact Us

601 LEXINGTON AVENUE,  
20TH FLOOR, NEW YORK,  
NY 10022, USA

LEVEL 10, UNITECH CYBER PARK,  
TOWER B, SECTOR – 39,  
GURGAON -122003, HARYANA

Email us at - [contact@bayslope.com](mailto:contact@bayslope.com)

Call us at:

+1 646.349.9293 (US)

+1 646.513.6768 (US)

+91 844.775.1586 (IN)